B cells and monocytes from patients with active multiple sclerosis exhibit increased surface expression of both HERV-H Env and HERV-W Env, accompanied by increased seroreactivity by Brudek, Tomasz et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
Retrovirology
Open Access Research
B cells and monocytes from patients with active multiple sclerosis 
exhibit increased surface expression of both HERV-H Env and 
HERV-W Env, accompanied by increased seroreactivity
Tomasz Brudek*1, Tove Christensen1, Lars Aagaard2, Thor Petersen3, 
Hans J Hansen3 and Anné Møller-Larsen1
Address: 1Department of Medical Microbiology and Immunology, University of Aarhus, DK-8000 Aarhus C, Denmark, 2Department of Molecular 
Biology, University of Aarhus, DK-8000 Aarhus C, Denmark and 3Department of Neurology, University of Aarhus, DK-8000 Aarhus C, Denmark
Email: Tomasz Brudek* - tb@microbiology.au.dk; Tove Christensen - tc@microbiology.au.dk; Lars Aagaard - laa@daimi.au.dk; 
Thor Petersen - thorpete@rm.dk; Hans J Hansen - hanshans@rm.dk; Anné Møller-Larsen - aml@microbiology.au.dk
* Corresponding author    
Abstract
Background: The etiology of the neurogenerative disease multiple sclerosis (MS) is unknown. The
leading hypotheses suggest that MS is the result of exposure of genetically susceptible individuals
to certain environmental factor(s). Herpesviruses and human endogenous retroviruses (HERVs)
represent potentially important factors in MS development. Herpesviruses can activate HERVs, and
HERVs are activated in MS patients.
Results:  Using flow cytometry, we have analyzed HERV-H Env and HERV-W Env epitope
expression on the surface of PBMCs from MS patients with active and stable disease, and from
control individuals. We have also analyzed serum antibody levels to the expressed HERV-H and
HERV-W Env epitopes. We found a significantly higher expression of HERV-H and HERV-W Env
epitopes on B cells and monocytes from patients with active MS compared with patients with stable
MS or control individuals. Furthermore, patients with active disease had relatively higher numbers
of B cells in the PBMC population, and higher antibody reactivities towards HERV-H Env and HERV-
W Env epitopes. The higher antibody reactivities in sera from patients with active MS correlate
with the higher levels of HERV-H Env and HERV-W Env expression on B cells and monocytes. We
did not find such correlations for stable MS patients or for controls.
Conclusion: These findings indicate that both HERV-H Env and HERV-W Env are expressed in
higher quantities on the surface of B cells and monocytes in patients with active MS, and that the
expression of these proteins may be associated with exacerbation of the disease.
Background
The cause of the inflammatory, neurodegenerative disease
multiple sclerosis (MS) remains unknown. Etiological
and epidemiological studies suggest that an infectious
agent or agents operating on a background of genetic sus-
ceptibility are probably involved in the pathogenesis [1].
Among the environmental factors human endogenous
retroviruses (HERV) and the ubiquitously present herpes-
viruses are gaining growing attention, substantiated by an
increasing number of reports suggesting their association
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with MS [2,3]. Recently, we have demonstrated increased
cellular immune responses towards different herpesvirus
and HERV antigens when they are concomitantly present
in lymphocyte stimulation assays [4]. The cellular
immune responses were synergistic in character and
tended to be higher in MS patients in comparison with
healthy controls.
This in vitro observation is pertinent only if herpesvirus
and HERV antigens are concurrently present in vivo in MS
patients. Herpesviruses are highly prevalent worldwide
and they all cause latent infections that may subsequently
become reactivated. HERVs are distributed in many copies
throughout the human genome, and are inherited in a
Mendelian fashion. Several herpesviruses are capable of
HERV activation as previously demonstrated for HERV-K
[5,6] and HERV-W [7,8]. We have recently shown that the
presence of inactivated herpesviruses can activate expres-
sion of HERVs in particle form in PBMCs from MS
patients in vitro, most probably resulting in the concurrent
presence of these two types of virus [9].
It has also been established that HERVs are present in acti-
vated form in vivo in MS patients. This is based on the
demonstration of activated HERV-H [10,11] and MSRV/
HERV-W [12,13] - virions - in blood from MS patients,
and increased levels of HERV-H, HERV-K, and HERV-W
RNA in MS brains [14]. HERV-W Env and Gag proteins
have also been found in brain tissue from MS patients
[15,16]. Our previous studies of humoral responses have
demonstrated elevated levels of antibodies towards
HERV-H Gag and Env epitopes in MS sera and cerebrospi-
nal fluid (CSF) [17,18], while others have reported anti-
MSRV/HERV-W antibodies in MS sera using a phage-dis-
play library of random pentadecapeptides as capture pep-
tides [19]. These authors reported specific reactivity to
four mimotopes in MS CSF. Two of these shared similarity
with the HERV-W Env sequence [19]. However, we have
subsequently found that all four mimotopes have higher
similarities to HERV-H Env sequences [2]. Anti-HERV
antibody reactivities will presumably be directed towards
epitopes on virions as well as on lymphocyte surfaces.
In this manuscript, we present the first evidence that both
HERV-H and HERV-W Envs are present at higher levels on
the surface of PBMCs from patients with active or stable
MS in comparison with PBMCs from healthy and neuro-
logical controls. Using flow cytometry, we have analyzed
the levels of specific Env epitopes on the surface of differ-
ent leukocyte populations. As a follow up to our previ-
ously published studies we have analyzed serum antibody
reactivities towards these particular HERV-H and HERV-W
Env epitopes, and correlated these reactivities with Env
expression levels.
Results
Western Blot and flow cytometric analyses of HERV-H Env 
and HERV-W Env expression on the surface of cells and 
particles obtained from MS cell cultures
The polyclonal anti-HERV-H/-W Env TM (transmembrane
region) and SU (surface unit region) rabbit antibodies
were used in Western Blot analyses of purified retroviral
particles from MS1946 cell culture, to detect whether
these Env epitopes are present on virion surfaces.
The polyclonal anti-HERV-H/-W Env antibodies were
raised towards equivalent but specific peptide epitopes:
two peptides were localized in the TM regions of HERV-H
and HERV-W Envs, respectively, and two peptides were
localized in the SU regions. The results are presented in
figure 1A. For HERV-H Env TM, a band of approximate
molecular mass of 120 kDa was present, whereas for
HERV-H Env SU a band of approximate molecular mass
of 60 kDa was found. Bands of approximate molecular
masses of 80 kDa, corresponding to both HERV-W Env
TM and HERV-W Env SU, were present in virions pro-
duced by the MS1946 cell culture. The 60, 80 and 120 kDa
bands were absent on blots incubated with the appropri-
ate pre-immune sera. The bands at 60 and 80 kDa are
likely to correspond to monomeric glycosylated Envs,
while the band at 120 kDa may represent envelope pro-
tein aggregates or protein dimers as described for other
retroviral Envs [20-23].
The differences in band sizes may be a result of HERV-H/
-W Env heterogenecity. At least three different ORFs for
HERV-H Env, and one (Syncytin 1) for HERV-W Env, sup-
plemented by a number of sequences with almost intact
coding capacity, are dispersed in the human genome [22-
27].
To compare the presence of HERV Env epitopes on virions
with expression of the same epitopes on cell surfaces of
the virion producing cell culture, we performed flow cyto-
metric analyses. The results presented in figure 1B corrob-
orate the Western Blot analyses as the cell culture
expresses both HERV-H Env and HERV-W Env epitopes.
However, whereas the equivalent HERV-W Env TM and
SU epitopes are detectable on the surface of the cells, they
are present at markedly lower levels than the HERV-H Env
TM and SU epitopes.
Flow cytometric analysis of HERV-H Env and HERV-W Env 
expression on PBMCs
PBMCs isolated from patients with active MS, stable MS,
from healthy controls and neurological non-inflamma-
tory disease controls were incubated with the anti-HERV-
H/-W Env anti-sera (Additional File: Supplementary fig.
1), and also with anti-CD4, anti-CD8, anti-CD14, or anti-
CD19 antibodies, allowing a concurrent determination ofRetrovirology 2009, 6:104 http://www.retrovirology.com/content/6/1/104
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HERV Env expression, and determination of different leu-
kocyte phenotypes.
The HERV-H Env and HERV-W Env TM and SU epitopes
were also found to be present on CD19+ (B cells) as on
CD14+ cells (monocytes), whereas we did not detect
either HERV-H Env or HERV-W Env epitopes on CD4+ T
cells or on CD8+ T cells (data not shown).
The surface expression of HERV-H Env TM epitopes on
CD19+ cells was significantly higher in patients with MS,
regardless of the disease activity, than in both groups of
control individuals (p ≤ 0.001)(fig. 2A and fig. 2C). The
CD19+ cell expression of HERV-W Env TM epitopes was
also significantly higher in both group of MS patients but
only when compared with healthy controls (p = 0.02).
CD14+ cell expression of HERV-H Env TM was signifi-
cantly higher in both MS patient groups compared with
neurological non-inflammatory disease controls (p  ≤
0.05).
Results obtained using anti-Env SU antibodies are pre-
sented in figure 2B and 2D. HERV-H Env SU epitope
expression was significantly higher on B cells and mono-
cytes in all groups of individuals compared with HERV-W
Env SU epitope expression (p < 0.01). The surface expres-
sion of the HERV-H Env SU epitope on CD19+ cells was
significantly higher in patients with active MS than in
patients with stable MS (p = 0.0001), healthy controls (p
= 0.04), and neurological controls (p  = 0.009). The
CD19+ cell expression of the HERV-W Env SU epitope
was significantly higher in the group of patients with
active MS compared with stable MS (p = 0.0014), healthy
controls (p  = 0.0008), and neurological controls (p  =
0.0009). Similarly, on CD14+ cells HERV-H Env SU and
HERV-W Env SU epitope expression levels were higher in
patients with active MS compared with stable MS patients
(for both SU epitopes, respectively p = 0.05, p = 0.05),
healthy controls (for both SU epitopes, respectively p =
0.03, p = 0.0001), and neurological controls (for both SU
epitopes, respectively p = 0.05, p = 0.0002).
Characterisation of leukocyte phenotypes
We characterised the basic leukocyte populations in the
PBMC samples from MS patients and healthy controls in
parallel with the quantification of HERV-H/-W Env
epitope expression on cell surfaces. The results are pre-
sented in figure 3.
Patients with active MS had a significantly higher number
of B cells compared with patients with stable MS, healthy
controls, or neurological non-inflammatory disease con-
trols. We did not find significant differences in the num-
bers of CD4+ T cells, CD8+ T cells, or monocytes.
Western blot analyses of OptiPrep purified HERV particles  from MS 1946 long-term, lymphoblastoid cell cultures Figure 1
Western blot analyses of OptiPrep purified HERV 
particles from MS 1946 long-term, lymphoblastoid 
cell cultures. Anti-HERV-H/-W Env TM and SU antibodies 
were raised in New Zealand white rabbits against 17-mer 
peptides localised at specific, but equivalent positions in the 
Env ORFs of HERV-H env62/H19 (Env H1TM: aa489-505; 
Env H3SU: aa 370-386) and of syncytin 1 (Env W1TM: aa415-
431, Env W3SU: aa301-317). Size markers are shown to the 
left. TM, SU -- anti-HERV Env TM/SU serum; PTM, PSU -- 
appropriate pre-immune control sera. A. Flow cytometric 
analysis of surface expression of HERV-H Env and HERV-W 
Env TM and SU epitopes on cells from MS 1946 long-term 
lymphoblastoid cell cultures. The grey peaks represent the 
fluorescence of cells incubated with human IgG; the peaks 
with dashed line represent fluorescence of the cells incu-
bated with pre-immune serum and FITC goat anti-rabbit anti-
bodies; and the peaks with solid line represent fluorescence 
of the cells incubated with anti-HERV-H/-W Env TM/SU anti-
sera and FITC goat anti-rabbit antibodies. Fluorescence indi-
ces are calculated as the ratio of the mean fluorescence of 
the cells incubated with anti-Env Abs to the mean fluores-
cence of the cells incubated with the appropriate control 
(pre-immune serum).Retrovirology 2009, 6:104 http://www.retrovirology.com/content/6/1/104
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Levels of anti-HERV-H Env and anti-HERV-W Env 
antibodies
Having demonstrated that the surface expression of
HERV-H/-W Env epitopes is higher on B cells and mono-
cytes from patients with active MS, we analyzed the sero-
logical reactivity towards these epitopes. Accordingly, the
peptides used for capture in this serological screening
were identical to the peptides used for rabbit immunisa-
tion.
Figure 4 presents the analysis of the serological reactivity
towards the HERV-H/-W Env peptide epitopes in sera
Flow cytometric analysis of surface expression of HERV-H Env and HERV-W Env on B-cells and monocytes from patients with  active MS (AMS), stable MS patients (SMS), healthy individuals (HC), and neurological non-inflammatory controls (NC) Figure 2
Flow cytometric analysis of surface expression of HERV-H Env and HERV-W Env on B-cells and monocytes 
from patients with active MS (AMS), stable MS patients (SMS), healthy individuals (HC), and neurological non-
inflammatory controls (NC). The results are presented as fluorescence indices calculated as the ratio of the mean fluores-
cence of the cells incubated with anti-Env Abs to the mean fluorescence of the cells incubated with the appropriate control 
(pre-immune serum). Mean values (2A) and scatter plots (2C) for cells incubated with anti-Env TM Abs. Mean values (2B) and 
scatter plots (2D) for cells incubated with anti-Env SU Abs. The standard errors for each group are presented. The significant 
differences (P ≤ 0.05) between the groups are shown. * - P ≤ 0.05; ** - P ≤ 0.01; ***- P ≤ 0.001 on column bar graphs 2A and 2B.Retrovirology 2009, 6:104 http://www.retrovirology.com/content/6/1/104
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from MS patients with active and stable MS as well as from
healthy and disease controls. Sera from MS patients with
active disease exhibited significantly higher levels of reac-
tivity to all four peptides compared with patients with sta-
ble MS and with control individuals. Moreover, the levels
of antibodies correlated with the levels of HERV-H/-W
Env epitopes expressed on B cells and monocytes from
patients with active MS, whereas such a correlation could
not be found for stable MS patients, or for either group of
control individuals (figure 5).
Discussion
An increasing number of reports indicate a role for HERVs
in MS pathogenesis. The two Gammaretroviruses, HERV-
H and HERV-W are activated in MS patients during peri-
ods with disease activity [10,13,17,18]. Moreover, previ-
ous demonstrations of retroviral RNA in plasma/serum
samples from MS patients indicate the presence of HERV
virions and/or HERV proteins [10,13].
A previous study has analyzed HERV mRNA levels in
brain and lymphocyte populations from 20 MS patients
unstratified for disease activity [28]. The present investiga-
tion is the first report of concomitant surface expression of
both HERV-H Env and HERV-W Env epitopes on PBMCs
from MS patients with active or stable MS, and controls.
In addition, we have extended the findings by analyses of
antibody reactivity towards these epitopes.
Initial investigations using flow cytometry demonstrated
the presence of HERV-H Env and HERV-W Env on the sur-
face of cells isolated from long-term MS cell cultures. Vir-
ions from the same cultures were analyzed by Western
Blotting demonstrating the concomitant presence of both
HERV-H and HERV-W Env epitopes in OptiPrep purified
virions. This illustrates the known complexity of the
HERV particles produced in MS [2]. Moreover, the differ-
ent sizes of bands in Western Blots suggest individual Env
expression patterns for HERV-H and HERV-W. In an ear-
lier study we have demonstrated that Wistar rats, immu-
nised with OptiPrep purified virions produced in long-
term MS cell cultures, develop a serological response
towards HERV-H Gag and Env derived synthetic peptides
[17]. The present results are more direct indications of the
presence of HERV Env epitopes on the virions produced in
the MS cell cultures.
We also present analyses of the expression of HERV-H Env
and HERV-W Env epitopes on the surface of PBMCs from
patients with active MS, stable MS, and from control indi-
viduals. Both envelope proteins were detected on B cells
and monocytes only, with the expression of HERV-H Env
epitopes generally higher than the expression of HERV-W
Env epitopes. Moreover, there were significantly higher
quantities of both Envs on individual cells from patients
with active MS compared with patients with stable MS and
the control groups.
The apparent differences in the expression of HERV-H/-W
Env TM and SU epitopes could be due to distinct features
in the molecular Env-membrane interactions [29], or may
be inherent in the assay as it could be due to differences in
the glycosylation of the envelope proteins. Several of the
HERV-H Env precursors are longer than the HERV-W Env
(Syncytin 1) precursor and contain more putative N-
linked glycosylation sites [20,22,23] which could affect
the epitope exposure and thus its interaction with anti-
bodies. An example is a putative glycosylation site at posi-
tion aa370 in the HERV-H Env SU epitope, as it has
previously been shown that glycosylation of HIV Env
epitopes can affect their conformation as well as their
interaction with antibodies [30].
Antibodies against TM region of HERV Envs have been
successfully used in immune assays including flow cytom-
etry and immunofluorescence staining by others, as they
are able to detect the TM region of a given Env protein [31-
34]. Furthermore, it was shown for anti-HIV Env TM anti-
bodies that they may utilize the cellular membrane to
access and bind to gp41 [35], and that the membrane-
embedded HIV Envs elicit broader immune responses
than soluble forms of Envs [36].
Flow cytometric analysis of different leukocyte populations in  PBMCs isolated from patients with active MS (AMS), stable  MS patients (SMS), healthy individuals (HC), and neurological  non-inflammatory controls (NC) Figure 3
Flow cytometric analysis of different leukocyte popu-
lations in PBMCs isolated from patients with active 
MS (AMS), stable MS patients (SMS), healthy individ-
uals (HC), and neurological non-inflammatory con-
trols (NC). The bars represent the percentage of CD19, 
CD4, CD8, and CD14 cells in 5 × 106 PBMCs. The mean val-
ues and the standard error for each group are presented, 
and the significant differences (P ≤ 0.05) between the groups 
are shown. * - P ≤ 0.05; ** - P ≤ 0.01; ***- P ≤ 0.001Retrovirology 2009, 6:104 http://www.retrovirology.com/content/6/1/104
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The expression of the Env epitopes exclusively on the sur-
face of B cells and monocytes may be a consequence of the
special relationship between HERVs and herpesviruses. It
is already established that herpesviruses can activate
HERVs [7-9,37-40] and it is likely that reactivated herpes-
viruses may transactivate HERVs at the transcriptional
level. Many indications also exist that herpesviruses may
be involved in MS pathogenesis. EBV, HHV-6, and VZV
are the strongest candidates for this involvement [41]. It is
well established that EBV persists within memory B cells
[42], whereas monocytes are a site of latency for HHV-6
[43]. VZV DNA has been demonstrated in MS patient
mononuclear cells in connection with disease exacerba-
tion [44]. Noteworthy in this context is that we have pre-
viously shown that the concomitant presence of HERV
and herpesvirus antigens induces synergistic cell-medi-
ated immune responses [4,45]. It has also been demon-
strated by others that patients with active MS have higher
specific cellular immunity towards synthetic HERV Env
TM peptides than patients with stable MS [46,47].
Concomitantly with the analyses of HERV Env expression,
we analyzed the actual composition of the PBMC popula-
tions. Significantly higher numbers of B cells were present
in the PBMCs from patients with active MS compared
with healthy controls. Thus, the higher number of B cells
together with the higher expression of HERV-H Env and
HERV-W Env epitopes will augment the total amount of
HERV Envs in active MS, while HERV Env expression is
lower and hence may be down-regulated in patients with
stable MS.
It is widely thought that T cells play a central role in MS
pathogenesis and they have previously been the main
focus of attention, since CD4+ T cells, as well as CD8+ T
cells, reactive to myelin antigens, are present in MS
patients and seem to be crucial in the development of
some types of demyelinating lesions [48-53]. The autore-
active CD4+ T cells in MS may be activated in the periph-
ery and once activated, they can cross the blood-brain
barrier (BBB) [54,55]. Furthermore, several features of MS
Seroreactivity to HERV-H Env and HERV-W Env derived peptides in patients with active MS (AMS), stable MS patients (SMS),  and healthy individuals (HC) Figure 4
Seroreactivity to HERV-H Env and HERV-W Env derived peptides in patients with active MS (AMS), stable MS 
patients (SMS), and healthy individuals (HC) and neurological  non-inflammatory controls (NC). The horizontal 
lines indicate median TRIFMA ratios for each group. Significant differences (P ≤ 0.05) between the groups are shown.Retrovirology 2009, 6:104 http://www.retrovirology.com/content/6/1/104
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Multiparameter regression between the levels of anti-HERV-H/-W Env blood serum antibodies measured by TRIFMA vs. the  levels of surface expression of HERV-H Env and HERV-W Env epitopes on B-cells and monocytes from patients with active MS  (AMS), stable MS patients (SMS), and healthy individuals (HC) measured by flow cytometry (expressed as fluorescence indices  calculated as the ratio of the mean fluorescence of the cells incubated with anti-Env Abs to the mean fluorescence of the cells  incubated with the appropriate control (pre-immune serum)) Figure 5
Multiparameter regression between the levels of anti-HERV-H/-W Env blood serum antibodies measured by 
TRIFMA vs. the levels of surface expression of HERV-H Env and HERV-W Env epitopes on B-cells and mono-
cytes from patients with active MS (AMS), stable MS patients (SMS), and healthy individuals (HC) measured 
by flow cytometry (expressed as fluorescence indices calculated as the ratio of the mean fluorescence of the 
cells incubated with anti-Env Abs to the mean fluorescence of the cells incubated with the appropriate control 
(pre-immune serum)). The solid line for CD19+ cells and dashed line for monocytes indicate the regression line. Correla-
tion coefficient (r2) and statistical (P ≤ 0.05) significance are shown.Retrovirology 2009, 6:104 http://www.retrovirology.com/content/6/1/104
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lesions suggest that Th1 mediated immune responses play
an important role in the inflammatory process [56]. A
prominent expansion of CD8+ memory T cells have also
been found in MS CSF and in MS brain tissue [57,58].
However, it is now emerging that other cell types, i.e. B
cells, and also other factors are important [59-61]. Unlike
activated T cells, B cells do not appear to cross the intact
BBB, whereas the occurrence of BBB damage in MS does
permit the entry of B cells and antibodies into the CNS
[62] presumably augmenting the characteristic intrathecal
antibody synthesis found in a majority of MS patients.
Furthermore, B-cell activation is associated with a more
serious clinical outcome in MS [63], and B cells, plasma
cells, and myelin-specific antibodies are present in some
MS plaques [64-66]. One of the roles of the T-cells could
be regulation of HERV expressing B cells. It is most likely
that HERV expression stimulates antibody production,
and in conjunction cytotoxic T cells and antibodies may
act synergistically in reducing the increased HERV expres-
sion, thereby probably diminishing the immune reactivity
and thereby also influence the pathogenesis of the actual
MS attack.
The role of HERV-expressing monocytes is more uncertain
and not extensively investigated, but besides being regu-
lated by CD4+ T cells, these cells are antigen-presenting
cells as are the B cells, which may contribute to T-cell reac-
tivity towards the expressed HERV epitopes.
The apparent link between B-cell expansion in PBMCs
and increased relapse-activity in MS is particularly inter-
esting in view of the increasing awareness of the impor-
tance of B cells in MS pathogenesis (and the evident
therapeutic potential in B-cell depletion [67]) although
the main focus so far has been the B cells involved in
intrathecal IgG synthesis in the CNS [68]. Our current
findings are confirmed by reports of an increased number
of B cells during MS relapses [61], and significantly
increased levels of the B-cell survival promoter APRIL in
MS patients [69]. Recently, short-lived plasma blasts were
identified as the main effector B cell population involved
in active inflammation in MS patients [70].
The elevated levels of HERV-H and HERV-W Env expres-
sion on B-cell and monocytes surfaces in samples from
patients with active MS found in the present study is also
closely reflected in the antibody response to HERV-H and
HERV-W Env peptide epitopes. We have demonstrated
significantly elevated levels of serum antibodies towards
four representative Env peptide epitopes (HERV-H SU and
TM, and HERV-W SU and TM) in samples from patients
with active MS. Both the TM and SU regions of retroviral
Envs are known to elicit serological responses [71], and
whereas the amino acid sequences of these peptide
epitopes clearly distinguish HERV-H Env from HERV-W
Env, they are localised at equivalent positions in HERV-H
and HERV-W Envs. This is completely consistent with our
previous findings of increased antibody reactivities
towards HERV-H/RGH-2 Env and Gag peptides associated
with high MS disease activity compared with control
groups such as patients with autoimmune diseases,
patients with other neurological diseases, or healthy rela-
tives of MS patients [17,18]. In the current study, serolog-
ical activities actually correlate with the levels of HERV-H/
-W Env surface expression on B cells and monocytes.
These consistent findings of higher anti-HERV antibody
reactivities in the active phases of the disease substantiate
a specific immune reactivity to HERVs in MS. Our findings
may be paralleled in the chronic progressive, neurological
disease HAM/TSP (HTLV-I (Human T-cell Leukaemia
Virus) Associated Myelopathy/Tropical Spastic Parapare-
sis) which is caused by the human exogenous retrovirus
HTLV-I. HAM/TSP is characterized by high levels of virus-
specific cytotoxic T cells concomitantly with high levels of
anti-HTLV-I Env antibodies in patient sera [72].
Apart from MS, HERVs have been implied in a number of
other autoimmune disorders. Examples of suggested
Gammaretroviral involvement in autoimmunity include
HERV-E and HERV-W in psoriasis [31,73], HERV-E in sys-
temic lupus erythematosus (SLE) [74,75], and HRES-1 in
SLE [76,77]. The direct and/or indirect roles of HERV-H
and HERV-W, the possible interactions between these two
HERVs, and between HERVs and herpesviruses in MS,
invites further investigations and there are several possible
mechanisms by which HERVs could cause MS [2].
Our present results advocate the hypothesis that expressed
ORFs from Gammaretroviruses such as HERV-H and
HERV-W, as well as the complex interactions of HERV-
expressing cells may play a role in MS development.
Methods
Blood samples
23 patients with active MS (18 females and 5 males, age
47 ± 11 years), 23 patients with stable MS (14 females and
9 males, age 49 ± 15 years), 22 healthy controls (11
females and 11 males, age 41 ± 13 years), and 11 patients
with epilepsy (6 females and 5 males, age 45 ± 13 years)
used as controls with an unrelated, neurological disease,
were enrolled in the study. Patients with epilepsy com-
prise a heterogeneous group, often with focal inflamma-
tory reactions as the cause of the seizures, which makes
these patients a relevant control group for MS. Moreover,
it has become increasingly evident that these inflamma-
tory reactions mediate some of the changes seen in con-
nection with seizures [78-81].
Stringent selection criteria were applied to all MS patients
to ensure that only individuals with "typical" and clini-
cally well-characterized relapsing-remitting MS were
included in the study. The MS patients were selected at theRetrovirology 2009, 6:104 http://www.retrovirology.com/content/6/1/104
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Neurology Department, Aarhus University Hospital, and
gave written informed consent to participate in the study.
The Central Denmark Region Committee on Biomedical
Research Ethics gave ethical approval for the sampling of
blood, culturing of cells from patients, and use in the
study. Information about the MS patients is provided in
table 1. All MS patients fulfilled the diagnostic criteria of
Poser et al., 1983 [82]. Relapsing-remitting (RR) MS is
defined in accordance with the Poser criteria as at least
two previous relapses in different CNS regions confirmed
by neurological examination. Stratification of MS disease
activity is also performed according to standard criteria:
Active MS is defined as at least one relapse within one year
prior to the examination (i.e. high annual relapse rate),
while stable MS is defined as the absence of disease activ-
ity for at least a year as determined by standard clinical cri-
teria. None of the MS patients or the control individuals
had any evidence of an infectious disease within the last 3
months prior to the study.
Venous blood was drawn at the respective clinics and
processed on the same day in our laboratory. PBMCs were
prepared by standard Isopaque-Ficoll centrifugation. The
separated cells were cryopreserved in RPMI with addition
of 20% human serum (HS) and 10% DMSO, at - 135°C
until use.
Cell cultures
The long-term, lymphoblastoid cell culture MS1946, orig-
inating from PBMCs from a patient with active MS, was
grown as described previously [83,84]. In brief, the cells
were grown at 0.5 × 106 cells/ml of RPMI-1640, supple-
mented with 10% inactivated human serum. Cells were
split three times a week and supplemented with fresh
medium. Twenty four hours before harvest of superna-
tants, the suspensions were supplemented with additional
fresh medium (approx. 30% of the total volume) to
obtain optimal growth conditions and thereby optimal
virus production. Only batches with sufficiently high ret-
rovirus production as confirmed by PERT (PCR-enhanced
reverse transcriptase assay) for reverse transcriptase activ-
ity [9,85] were used for virus purification.
Anti-HERV Env Antibodies
Polyclonal Anti-HERV-H Env and anti-HERV-W Env anti-
bodies were raised in New Zealand White rabbits against
16-mer peptides localised at equivalent positions in the
Env ORFs of HERV-H env62/H19 (Env H1TM: aa489-
505; Env H3SU: aa 370-386) [22,23] and syncytin 1 (Env
W1TM: aa415-431, Env W3SU: aa301-317) [25], respec-
tively. These peptide sequences fulfil the criteria of immu-
nogenicity, and they are localised at equivalent positions
in the HERV-H and HERV-W Envs, while having highly
dissimilar amino acid sequences. Both the peptides and
the anti-sera were prepared by Sigma-Genosys, UK. Preim-
mune sera were collected before immunisation. Two rab-
bits were immunised with each peptide, boosted 3 times,
and after the final boost, peripheral blood was collected
from each rabbit for subsequent measuring of anti-pep-
tide antibodies.
Table 1: Clinical data for MS patients: a -- active MS; RR -- relapsing-remitting; F -- female; M -- male.
MS patient MS type Age (years) Gender MS patient MS type Age (years) Gender
1 RR a 28 M 24 RR 56 F
2 RR a 70 F 25 RR 59 F
3 RR a 34 F 26 RR 63 F
4 RR a 40 F 27 RR 50 F
5 RR a 53 F 28 RR 65 M
6 RR a 62 M 29 RR 55 M
7 RR a 35 M 30 RR 29 F
8 RR a 56 F 31 RR 63 F
9 RR a 37 F 32 RR 31 M
10 RR a 53 M 33 RR 58 M
11 RR a 30 M 34 RR 23 M
12 RR a 38 F 35 RR 43 M
13 RR a 60 F 36 RR 58 F
14 RR a 54 F 37 RR 66 M
15 RR a 30 F 38 RR 57 F
16 RR a 51 F 39 RR 35 M
17 RR a 53 F 40 RR 39 F
18 RR a 53 F 41 RR 83 F
19 RR a 58 F 42 RR 56 F
20 RR a 51 F 43 RR 40 F
21 RR a 49 F 44 RR 26 F
22 RR a 44 F 45 RR 28 F
23 RR a 60 F 46 RR 43 MRetrovirology 2009, 6:104 http://www.retrovirology.com/content/6/1/104
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The specificity and cross-reactivity of the anti-HERV-H/-W
Env antisera against the peptides were analyzed using
TRIFMA assays. The anti-HERV-H Env epitope antisera
were at least a 1000 times more reactive towards the
HERV-H Env peptides than towards HERV-W Env pep-
tides, and vice versa (data not shown).
Virion purification and Western Blotting
The expression of HERV-H and HERV-W Env epitopes on
the virions produced by the long-term MS1946 cell cul-
ture was analysed by Western Blotting of purified parti-
cles. These virions were purified by ultracentrifugation of
800 ml samples of cell culture supernatants (1.2 × 106
cells/ml) in self-generating Iodixanol gradients
(Nycomed, Norway) as described in detail elsewhere [86],
and fractionated. Fractions with high reverse transcriptase
activity as measured by PERT were pooled, suspended in
TNE (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM
EDTA) with 0.1% HSA (human serum albumin) and
stored at -70°C until use.
The pooled virion-containing gradient fractions were
loaded onto 4-12% Bis-Tris precast gels, electrophoresed
in MOPS buffer (Criterion TM XT system, Biorad, Rich-
mond, CA, USA), and electrophoretically transferred to
Hybond nitrocellulose membranes in transferbuffer (25
mM Tris-HCl, 192 mM Glycine, 20% EtOH, 0,1% SDS,
pH 8.5). Relative molecular sizes were interpolated from
curves constructed on the basis of coloured marker pro-
teins (Biorad Richmond, CA, USA, Precision standard).
After incubation with the primary, polyclonal rabbit anti-
bodies (diluted 1/2500) at room temperature overnight,
the blots were treated with horseradish peroxidase-
labeled secondary goat anti-rabbit antibodies (diluted 1/
4000)(DAKO, Denmark) followed by enhanced chemilu-
minescence reagent (Super Signal West Pico, Pierce Bio-
technologies, Rockville, USA). Blots were visualised using
a Kodak ID Image Station.
Flow Cytometric Analysis
Multi-colour flow cytometry was performed to determine
both the phenotypes of the cells, and HERV-H Env and/or
HERV-W Env cell surface expression. The phenotypes were
determined using monoclonal antibodies, anti-CD19-PE
(cat.no. 12-0199), anti-CD4-PE-Cy5 (cat.no. 15-0049),
anti-CD8-PE-Cy7 (cat.no. 25-0088), and anti-CD14-PE-
Cy7 (cat.no. 25-0149) purchased from eBioscience. The
anti-HERV-H Env and anti-HERV-W Env antibodies
described above were used for HERV-H and HERV-W Env
epitope detection, visualised using goat anti-rabbit IgG,
F(ab')2 conjugated with FITC (PIERCE, cat. no. 31573).
Isotype controls included mouse IgG1PE, PE-Cy5, and PE-
Cy7 (eBioscience cat. no. 12-4714, 15-4714, 25-4714).
Pre-immune sera from the appropriate rabbits were used
as controls for the anti-Env antibodies. The monoclonal
antibodies were used in concentrations as suggested by
the manufacturer. The polyclonal rabbit antibodies were
diluted 1/1000 before use. Prior to staining with antibod-
ies all PBMC samples were incubated with human IgG
(Statens Serum Institute, Beriglobin, cat. no. 2948) in a
concentration of 100 μg/106 cells/ml to avoid non-spe-
cific antibody binding.
Flow cytometry analysis was performed on a Beckman
Coulter Cytomics FC500 flow cytometer. The data were
analyzed using Flow-Jo v.7 software (Treestar, San Carlos,
CA, USA). A total of at least 50,000 events were analyzed
for each sample.
The results from the relative quantification of HERV-H
Env and HERV-W Env epitope expression are presented as
fluorescence (FL) indices, which were obtained by divid-
ing the mean fluorescence of the cells incubated with anti-
Env antibodies by the mean fluorescence of cells incu-
bated with the appropriate pre-immune control serum.
Time-Resolved Immunofluorometric Assay (TRIFMA) for 
anti- Env peptide antibodies
TRIFMA is a highly sensitive and reliable method for anti-
body detection, using europium-labelled secondary anti-
bodies. The peptides used for capture were the same as the
peptides used for raising the polyclonal anti-HERV-H Env
and anti-HERV-W Env rabbit antibodies. The assay was
performed essentially as described previously [17,18]. In
brief, sera were diluted 1/500 in TBS/Tween and tested in
duplicate. The fluorescence was measured using a time-
resolved plate fluorometer (LKB, Wallac). Results are pre-
sented as TRIFMA ratios, defined as individual measure-
ments in relation to the mean of TRIFMA controls. As
TRIFMA inter-assay controls, 8 sera from healthy individ-
uals representing both high and low responders were used
[18]. The control sera were included in all TRIFMA assays.
Statistical analysis
For statistical calculations, Mann-Whitney testing and
multiple regression testing were performed using Graph-
Pad Instat ver.3. For TRIFMA, the highest and the lowest
responder were excluded from each group before the anal-
ysis was performed.
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